Zafgen Opens A New Front In Its Obesity Strategy: Prader-Willi Syndrome
Today Zafgen announced its initial results from proof-of-concept study in patients with an obesity-related orphan disease called Prader-Willi Syndrome (PWS). The news was also covered by Andrew Pollack in the NY Times this morning (here) so I won’t bother with the specifics – it showed meaningful improvements for several parameters affecting PWS patients and offers real promise.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Bruce Booth Source Type: news
More News: Eating Disorders & Weight Management | Obesity | Pharmaceuticals | Prader-Willi Syndrome | Study